Angel Adegbesan is a Business Reporter at various esteemed publications including the Toronto Star and Financial Post. She focuses on themes such as medicine and healthcare, alternative medicine, finance, and trading, often exploring topics related to markets, biotech, and nutrition. Angel's work has been featured in prominent outlets like Bloomberg News, The Washington Post, and Fortune.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Angel Adegbesan's articles predominantly focus on investment analysis within the healthcare and pharmaceutical industry, often supported by cited data. To effectively reach out to her, consider providing well-researched insights related to stock market movements, drug development or financial impacts within the biotech and pharmaceutical sectors.
Given Angel’s emphasis on citing data in investment analysis, she may be particularly responsive to pitches that offer proprietary data or unique analyses relevant to the performance of companies in the healthcare and pharmaceutical industries.
As there is no specific geographic focus mentioned for Angel's coverage, it appears that she covers global developments in healthcare and pharmaceuticals without a particular regional bias.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angel Adegbesan, Sophia Vahanvaty
Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus.
By: Sophia Vahanvaty, Angel Adegbesan
(Bloomberg) -- Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus. Most Read from BloombergManchester Is Giving London a Run for Its MoneyBoston’s Broke and Broken Transit System Hurts Downtown RecoveryA Floating Island in Baltimore Raises Hope for a Waterfront RevivalA Warehouse Store Promises Housing for
By: Angel Adegbesan
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.
“Spring forward, fall back” is a twice-a-year part of life in roughly 70 countries around the world. In the US, where the practice is more than a century old, lawmakers are considering measures that would end clock changes and make daylight saving time permanent. That would mean later sunrises and sunsets for half the year. There’s evidence that the public health effect would be mixed: fewer car accidents and heart attacks caused by time shifts, but potentially a loss of sleep quality for almost
By: Angel Adegbesan
Most Read from Bloomberg Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential
Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment.
A recently debuted nursing home operator, PACS Group Inc., made a violent reversal this week, erasing around $2.5 billion from its cofounders’ fortunes.
By: John Tozzi, Angel Adegbesan, Antonia Mufarech, David Voreacos
This is a special edition of Prognosis from Bloomberg reporters who were at the Manhattan hotel where UnitedHealth’s Brian Thompson was shot Wednesday and others who spoke with eyewitnesses.
By: Angel Adegbesan, Lisa Pham
In This Article LLY ZEAL.CO VKTX AMGN NVO
By: Angel Adegbesan, Lisa Pham
Die Aktien der Hersteller für Medikamente gegen Fettleibigkeit fuhren 2024 Achterbahn. Die enttäuschenden Studienergebnisse für das experimentelle Adipositas-Mittel CagriSema von Novo Nordisk beenden nun das volatile Jahr.
(833) 317-6278 
